- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Submit a Manuscript
- Subscription Information
- Table of Contents
Lymphoma
Volume 2012 (2012), Article ID 290685, 10 pages
doi:10.1155/2012/290685
Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors
1Epigenomic Medicine, Baker IDI Heart and Diabetes Institute, The Alfred Medical Research and Education Precinct,
Melbourne, VIC 3004, Australia
2Department of Pathology, The University of Melbourne, Parkville, VIC 3010, Australia
Received 30 May 2012; Accepted 23 June 2012
Academic Editor: Vincent Ribrag
Copyright © 2012 Annabelle L. Rodd et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to Cite this Article
Annabelle L. Rodd, Katherine Ververis, and Tom C. Karagiannis, “Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors,” Lymphoma, vol. 2012, Article ID 290685, 10 pages, 2012. doi:10.1155/2012/290685